Growth hormone treatment in adults with growth hormone deficiency: the transition.
about
The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapMulti-centre phase IV trial to investigate the immunogenicity of a new liquid formulation of recombinant human growth hormone in adults with growth hormone deficiency.
P2860
Growth hormone treatment in adults with growth hormone deficiency: the transition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Growth hormone treatment in adults with growth hormone deficiency: the transition.
@en
Growth hormone treatment in adults with growth hormone deficiency: the transition.
@nl
type
label
Growth hormone treatment in adults with growth hormone deficiency: the transition.
@en
Growth hormone treatment in adults with growth hormone deficiency: the transition.
@nl
prefLabel
Growth hormone treatment in adults with growth hormone deficiency: the transition.
@en
Growth hormone treatment in adults with growth hormone deficiency: the transition.
@nl
P2860
P356
P1476
Growth hormone treatment in adults with growth hormone deficiency: the transition.
@en
P2093
M E Molitch
P2860
P2888
P304
P356
10.1007/BF03347046
P577
2011-01-26T00:00:00Z